uniQure N.V. Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
uniQure N.V. (QURE) had Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount of $22.32 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized · last filed 2025-02-27
- 2024-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $22.32M.
- 2024-08-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $3.20M.
- 2023-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $49.46M.
- 2022-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $49.53M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount |
|---|---|
| 2024-12-31 | $22.32M 10-K · filed 2025-02-27 |
| 2024-08-31 | $3.20M 10-Q · filed 2024-11-05 |
| 2023-12-31 | $49.46M 10-K · filed 2024-02-28 |
| 2022-12-31 | $49.53M 10-K · filed 2023-02-27 |
| 2021-12-31 | $49.64M 10-K · filed 2022-02-25 |
| 2020-12-31 | $39.74M 10-K · filed 2021-03-01 |
| 2019-12-31 | $32.50M 10-K · filed 2020-03-02 |
| 2018-12-31 | $23.48M 10-K · filed 2019-02-28 |
| 2018-09-30 | $26.12M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $23.63M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $25.42M 10-Q · filed 2018-04-30 |
| 2017-12-31 | $14.36M 10-K · filed 2018-03-14 |
| 2017-09-30 | $14.79M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $14.24M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $14.40M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $9.98M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |